Redeye regards the recently received RMAT (Regenerative Medicine Advanced Therapy) designation from FDA as a clear boost for Immunicum. Importantly, it could potentially open for an accelerated approval pathway for ilixadencel in kidney cancer. Further regulatory feedback could come as early as end of Q2. We increase our base case to SEK 15-16 to model for some likely benefits of this expedited program.